Data source: We conducted a review of published literature and identified 32 trials reviewing incidence of SGLT2 inhibitor-related amputation. Results: The potential increased risk for amputation is mostly of the lower extremities. Of the SGLT2 inhibitors currently available, canaglifl...
Dapagliflozin, developed jointly by Bristol-Myers Squibb and AstraZeneca, is a novel anti-diabetic drug. It belongs to the class of SGLT2 inhibitors, which are used as an important option in the treatment of type 2 diabetes. Dapagliflozin works by inhibiting sodium-glucose cotransporter 2, a pr...
2023) [49]. Starvation mimicry has been used to show that SGLT-2 inhibitor modulation of mitochondrial function and viability involves processes of autophagy
SARS-CoV-2 sites of infection and complications in diabetic patients. As is the case for SARS-CoV, SARS-CoV-2 uses the ectopeptidase ACE2 as an entry site in human host cells. ACE2 is part of the renin-angiotensin system, responsible for the termination of the angiotensin signal, promotin...
nonsteroidal anti-inflammatory drug PROactive: Prospective Pioglitazone Clinical Trial in Macrovascular Events PUFA: polyunsaturated fatty acid QR: quick release RA: receptor agonist SHEP: Systolic Hypertension in the Elderly Program SGLT2: sodium glucose co-transporter 2 ...
Sodium-glucose cotransporter-2 (SGLT2) inhibitors also have a uricosuric effect, probably induced by the inhibition of GLUT9b in the collecting duct50). On the other hand, pyrazinamide may induce hyperuricemia via the stimulation of URAT11). Regulation of Urate Transporter...
The failing heart is energy deficient, has diminished glucose, and depends on fatty acid oxidation [8]. Free fatty acids contribute to arrhythmias. Drug therapy, particularly angiotensin receptor-neprilysin inhibitor (ARNI) – sacubitirl/valsartan and sodium-glucose cotransporter-2 inhibitor (SGLT2i)...
(SGLT2), which causes a reduction in the reabsorption of filtered glucose. The drug also causes the patient to excrete excess glucose through their urine, lowering plasma glucose concentrations overall. This medication has been shown to lower A1C levels by 0.7% to 1% but is particularly favored...
SGLT2 inhibitor, ACEI, or angiotensin receptor blocker prescriptions among patients with diabetes and CKD [20]. In low- or middle-income countries (LMICs), the gap between evidence and implementation is even wider given the high cost and inconsistent availability of these medications, despite ...
Loop diuretics Furosemide, torsemide Good when GFR is low, good for heart failure Yes Thiazide diuretics Hydrochlorothiazide, metolazone, indapamide Good for BP, especially in the Black population Yes SGLT2 inhibitor Empagliflozin, canagliflozin, dapagliflozin Diabetes control, delays CKD progression, car...